Welcome to “JDD January 2026 Issue Highlights,” your guided tour through this month’s must-read studies, curated by the Journal of Drugs in Dermatology Editorial Team. This issue carries a Special Focus on Aesthetic Treatments, bringing together practical safety analyses, regulatory perspectives on regenerative medicine, advances in pigmentary and procedural care, and health‑equity research that informs everyday clinical decisions. Whether you’re weighing adverse‑event data for new metabolic therapies, refining pigmentary treatment plans, or navigating access to advanced atopic dermatitis agents, these selections offer actionable takeaways to strengthen patient care.
Explore this month’s top picks below:
Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018–2024
A pharmacovigilance study using dulaglutide as reference, identifying sex, age, and GLP‑1 receptor agonist type as independent predictors of cutaneous adverse events — essential for clinicians counseling patients initiating these agents.
Regulatory Landscape of Regenerative Dermatology: Current Frameworks and Future Directions
A clear-eyed review of regulatory frameworks and why understanding mechanisms of action matters for product selection, safety, and intended effects on skin structure.
A Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma
Encouraging efficacy data for malassezin as a novel topical treatment for melasma — a potential alternative for pigment management.
Clinical Evaluation of a Thiamidol-Based Regimen With SPF Compared With SPF Alone for Facial Hyperpigmentation
Practical evidence supporting integration of thiamidol-based regimens into routine photoprotection strategies to better address facial hyperpigmentation.
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States
An important analysis highlighting differences in disease severity and access to advanced AD therapies — prompting clinicians and systems to address treatment inequities.
Sunless Tanners in Dermatology: A Review of Ingredients, Efficacy, and Safety Profiles
A useful primer for counseling patients about formulation differences, expectations, and safety considerations when using sunless tanning products.
Combined Use of Relabotulinum Toxin A and NASHA Gel Skinbooster for Rejuvenation of the Upper Third of the Face
Procedural data demonstrating improved lateral eyebrow tail elevation with this combination approach.
Characterizing Safety Outcomes of a Dermal Filler: Injection Site and Timing Insights From the MAUDE Database
A safety-focused evaluation categorizing adverse events associated with Juvéderm Volbella injections — valuable for patient counseling and risk mitigation.
Private Insurance Coverage for Botulinum Toxin for Primary Axillary Hyperhidrosis: A Cross-Sectional Analysis
A practical policy snapshot showing that surveyed private insurers provide coverage for botulinum toxin after failure of standard therapies — helpful when setting patient expectations about authorization.
Photodistributed Hyperpigmentation Associated With COVID-19 Vaccination
A case‑oriented report raising awareness of a rare but potentially cosmetically important adverse event following COVID‑19 vaccination — a reminder to include recent vaccination history when evaluating new photodistributed hyperpigmentation.
Find more JDD Issue Highlights here.